Page 4

2026-09-27 · 2026-09 / week-4

GIPR Cleared Loci, but the Reload Warrants Do Not Clear 10/5

Summary: Generation Income Properties has confirmed that it paid off Loci Capital’s remaining $4.16 million preferred interest, a real reduction in a near-term claim. But the cash came principally from an induced warrant...

2026-09-27 · 2026-09 / week-4

LEGN’s five-year remission data still needs a cash bridge

Summary: A fresh 20-patient follow-up found half of an earlier-line CARVYKTI cohort alive and progression-free five years after a single infusion without maintenance therapy. The evidence is clinically meaningful, but it...

2026-09-26 · 2026-09 / week-4

Knife River’s activist margin target is not yet a cash bridge

Summary: Starboard wants Knife River to reach at least 22% Adjusted EBITDA margins by FY2029 and evaluate strategic alternatives. Knife River says it will engage but has not adopted that target or announced a sale proces...

2026-09-26 · 2026-09 / week-4

Prime Medicine’s IND clearance opens trials, not a 10/5 long

Summary: FDA clearance lets Prime Medicine begin clinical testing of PM647; it does not show that the gene editor works safely in people. The first post-announcement regular session reversed the after-hours jump and trad...

2026-09-25 · 2026-09 / week-4

SFIX’s 22% regular-session gap leaves little short downside

Summary: Stitch Fix’s FY2027 revenue guide trailed cited consensus after active clients declined again; the first regular session after earnings closed near $2.20, down about 22% on roughly 14 million shares. Yet at that...